Immix Biopharma, Inc. (ticker: IMMX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of IMMX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. IMMX reported $20.00M in revenue and -$10.09M for the period ending 2022-12-08, with operating cash flow of -$9.83M. Cash and equivalents stood at $79.25M (up 397.8% year-over-year). Total assets of $95.82M exceed total liabilities of $11.45M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
IMMX SEC Filings
Full cached SEC EDGAR filing history for IMMX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.